Prelude Therapeutics Inc: 5%+ holders

As of November 8, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Prelude Therapeutics Inc. The largest reported stake is Orbimed Advisors LLC's, at 16%. 6 filings are on record since November 7, 2025 (Schedule 13D/A, April 23, 2026).

Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies ↓

Sell to companies like Prelude Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-07-08 · Reporting person: Soleus Private Equity Fund III, L.P. · Sole voting: 0 · Shared voting: 675,676 · Sole dispositive: 0 · Shared dispositive: 675,676 · SCHEDULE 13G, 2026-07-08
• Filed 2026-04-28 · Holder: RA Capital Management, L.P. · Percent: 9.9% · SCHEDULE 13G
• Filed 2026-04-23 · Holder: Orbimed Advisors LLC · Percent: 16% · SCHEDULE 13D/A
• Filed 2026-04-22 · Holder: Baker Bros. Advisors LP · Percent: 15.5% · SCHEDULE 13D/A
• Filed 2026-02-13 · Holder: Vaddi Krishna · Percent: 13.15% · SCHEDULE 13G/A

Prelude Therapeutics Inc has 6 Schedule 13D or 13G filings on record since 2025-11-07. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Prelude Therapeutics Inc and the warning signs.

See Prelude Therapeutics Inc's free Snapshot Watch Prelude Therapeutics Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Prelude Therapeutics Inc and the records around it.

Prelude Therapeutics Inc elsewhere on the record

• Leadership changes Apr 2026
• Who owns it

Companies that share a holder

• Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026), INVIVYD, INC. (Feb 2026)
• Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
• ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)

Want the whole picture on Prelude Therapeutics Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Prelude Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Prelude Therapeutics Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Prelude Therapeutics Inc by CUSIP 74065P101 and gives its principal executive office as 175 Innovation Boulevard, Wilmington, DE 19805 (SCHEDULE 13G, 2026-07-08).

Purpose of Transaction (Item 4)

Baker Bros. Advisors LP

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 6 below is incorporated herein by reference. On April 20, 2026, Prelude Therapeutics Incorporated (the "Issuer") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Citizens JMP Securities LLC (the "Underwriters"), related to a public offering (the "Offering") of 18,018,014 shares of common stock of the Issuer ("Common Stock"), at a price to the public of $4.44 per share and in lieu of Common Stock to investors who so chose, prefunded warrants to purchase up to 2,252,252 shares of the Issuer's Common Stock (the "Prefunded Warrants"), at a price to the public of $4.4399 per warrant with an exercise price of $0.0001 per share. The Offering closed on April 21, 2026. Pursuant to the Offering, 667 and Life Sciences purchased 114,601 and 2,137,651 Prefunded Warrants, respectively, at the offering price of $4.4399 per share, totaling 2,252,252 Prefunded Warrants in the aggregate. Each of 667 and Life Sciences purchased the Prefunded Warrants with their working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-22; the filing has the rest

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-23; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Prelude Therapeutics Inc

Who owns Prelude Therapeutics Inc?

On this page, 6 holders' latest ownership filings report 5% or more of Prelude Therapeutics Inc: Orbimed Advisors LLC (16%, Schedule 13D/A, filed 2026-04-23), Baker Bros. Advisors LP (15.5%, Schedule 13D/A, filed 2026-04-22), Vaddi Krishna (13.15%, Schedule 13G/A, filed 2026-02-13), Incyte Corp (9.9%, Schedule 13G, filed 2025-11-07) and RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-04-28); 1 more is listed above.

Who are the largest shareholders of Prelude Therapeutics Inc?

By the share each holder's latest filing reports, the largest holders of Prelude Therapeutics Inc on this page are Orbimed Advisors LLC (16%), Baker Bros. Advisors LP (15.5%) and Vaddi Krishna (13.15%).

When did Orbimed Advisors LLC buy into Prelude Therapeutics Inc?

The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-04-23, reporting 16%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Prelude Therapeutics Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Prelude Therapeutics Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Prelude Therapeutics Inc is mentioned again
• Find former Prelude Therapeutics Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes